Protalix Biotherapeutics, Inc.
A biopharmaceutical company based in Israel, Protalix makes medicines for rare diseases by growing therapeutic proteins in plant cells. Its signature product, Elelyso, treats Gaucher disease and was the first plant-cell-made protein the FDA ever approved, developed with Pfizer. Founded in 1993 by a plant biochemist, the company grows engineered carrot cells as living bioreactors instead of animal cells.
Granted 459.0K · Bought 120.5K
Granted 90.9K
Granted 7.5K · Bought 129.0K
Granted 25.0K
Granted 7.5K
Granted 7.5K · Sold 168
Granted 7.5K
Granted 7.5K
Granted 7.5K
Granted 7.5K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bashan DrorPRESIDENT AND CEO, Director · 5 transactions | +29.7% | 2.53M | 459.0K | 120.5K | — |
| Rubin EyalSr. VP and CFO · 1 transaction | +15.9% | 660.9Kas of Sep 2024 | 90.9K | — | — |
| Schwartz AharonDirector · 2 transactions | — | 310.5K | 7.5K | 129.0K | — |
| Naos YaronSr. VP, Operations · 1 transaction | +12% | 232.9K | 25.0K | — | — |
| Boudes Pol FDirector · 1 transaction | — | 7.5K | 7.5K | — | — |
| Bar-Shalev AmosDirector · 2 transactions | — | 7.5K | 7.5K | — | 168 |
| Ben Zvi ShmuelDirector · 1 transaction | — | 7.5K | 7.5K | — | — |
| Elze ChristianDirector · 1 transaction | — | 7.5K | 7.5K | — | — |
| Forster EliotDirector · 1 transaction | — | 7.5K | 7.5K | — | — |
| Melincoff Gwen ADirector · 1 transaction | — | 7.5K | 7.5K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +249.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.